The decision to reimage following extravasation in diagnostic nuclear medicine
Open Access
- 21 April 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 3
Abstract
The primary goal of diagnostic nuclear medicine is to provide complete and accurate reports without equivocation or disclaimers. If specific clinical questions cannot be answered because of radiopharmaceutical extravasation, the imaging study may have to be repeated. The decision to reimage is based on several factors including the diagnostic quality of the images, additional patient radiation dose, patient burden, and administrative constraints. Through process improvement efforts, nuclear medicine departments can significantly reduce the frequency of extravasation and thereby also the need for reimaging. Communication with the patient is important any time extravasation may impact their immediate or future care. The circumstances and potential ramifications should be explained, and patient concerns should be addressed. Although recent arguments have been made in favor of investigating and addressing only those extravasations which result in serious patient injury, patients and their referring physicians deserve to know any time their nuclear medicine study may have been impacted.Keywords
This publication has 33 references indexed in Scilit:
- Radionuclides in Nephrourology, Part 1: Radiopharmaceuticals, Quality Control, and Quantitative IndicesJournal of Nuclear Medicine, 2014
- Extravasation des médicaments radiopharmaceutiques : mesures préventives et prise en charge recommandées par la SoFRa (Société française de radiopharmacie)Annales Pharmaceutiques Françaises, 2013
- Disclosure of “Nonharmful” Medical Errors and Other EventsArchives of Surgery, 2012
- Extravasation of a Therapeutic Dose of 131I-Metaiodobenzylguanidine: Prevention, Dosimetry, and MitigationJournal of Nuclear Medicine, 2011
- FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV MeasurementsFrontiers in Oncology, 2011
- Detection of 90Y Extravasation by Bremsstrahlung Imaging for Patients Undergoing 90Y-Ibritumomab Tiuxetan TherapyJournal of Nuclear Medicine Technology, 2010
- Valoración del estado de ansiedad de los pacientes que reciben un tratamiento con radioyodo o son sometidos a una exploración de ganglio centinela en el servicio de Medicina NuclearRevista Española de Medicina Nuclear, 2010
- Extravasation of Yttrium-90 Ibritumomab Tiuxetan: A Case StudyClinical Journal of Oncology Nursing, 2008
- Infiltration and ExtravasationAJN, American Journal of Nursing, 2007
- Increased cancer incidence after radioiodine treatment for hyperthyroidismCancer, 2007